Arena Pharmaceuticals

$73.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.06 (+2.88%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ARNA and other stocks, options, and ETFs commission-free!

About ARNA

Arena Pharmaceuticals, Inc. Common Stock, also called Arena Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA. The listed name for ARNA is Arena Pharmaceuticals, Inc. Common Stock.

CEO
Amit Dilip Munshi
Employees
363
Headquarters
San Diego, California
Founded
1997
Market Cap
4.55B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
666.97K
High Today
$73.82
Low Today
$69.21
Open Price
$71.91
Volume
617.80K
52 Week High
$90.19
52 Week Low
$32.95

ARNA News

BenzingaMar 3

Return On Capital Employed Overview: Arena Pharmaceuticals

During Q4, Arena Pharmaceuticals's (NASDAQ:ARNA) reported sales totaled $37.00 thousand. Despite a 23.83% in earnings, the company posted a loss of $122.35 mill

ARNA Earnings

-$2.28
-$1.88
-$1.48
-$1.08
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$1.85 per share
Actual
-$2.10 per share
Replay Earnings Call

You May Also Like

RWGV
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure